Thursday, February 06, 2020 3:59:57 PM
@Knowchit
Recent GNPX News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:15:54 PM
- Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer • PR Newswire (US) • 05/14/2024 12:31:00 PM
- Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors • PR Newswire (US) • 05/13/2024 12:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:11:07 PM
- Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner • PR Newswire (US) • 05/08/2024 10:08:00 PM
- Genprex to Present and Participate at Upcoming May Investor and Industry Conferences • PR Newswire (US) • 05/01/2024 12:31:00 PM
- Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting • PR Newswire (US) • 04/09/2024 12:31:00 PM
- Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer • PR Newswire (US) • 04/03/2024 12:31:00 PM
- Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System • PR Newswire (US) • 04/02/2024 12:31:00 PM
- Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • PR Newswire (US) • 03/22/2024 08:10:00 PM
- Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • PR Newswire (US) • 03/19/2024 05:24:00 PM
- Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • PR Newswire (US) • 03/19/2024 12:36:00 PM
- Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers • PR Newswire (US) • 03/12/2024 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 02:18:38 PM
- Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting • PR Newswire (US) • 03/06/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 01:45:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 09:34:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 09:32:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 09:28:09 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:14:47 PM
- Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators • PR Newswire (US) • 02/07/2024 01:15:00 PM
- Genprex to Present at Upcoming BIO CEO & Investor Conference • PR Newswire (US) • 02/06/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2024 01:15:59 PM
- Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer • PR Newswire (US) • 02/05/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 12:30:14 PM
FEATURED Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • May 17, 2024 11:00 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM